MannKind Corporation
30930 Russell Ranch Road
Suite 301
Westlake Village
California
91362
United States
Website: http://www.mannkindcorp.com/
375 articles with MannKind Corporation
-
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
2/23/2023
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
2/22/2023
MannKind Corporation (Nasdaq: MNKD) announced today that it will present an oral presentation describing meal challenge results at the 16th International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Berlin February 22-25.
-
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
2/16/2023
MannKind Corporation will release its 2022 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM on Thursday, February 23, 2023.
-
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
1/24/2023
MannKind Corporation announced today that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven B. Binder, will participate in the Lytham Partners Investor Select Conference taking place virtually on Tuesday January 31, 2023.
-
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
1/23/2023
MannKind Corporation today announced clofazimine inhalation suspension (MNKD 101) will advance to an adaptive Phase 2/3 study. Additionally, a paper has been published in the American Society for Microbiology journal.
-
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
1/5/2023
MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 2023 Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, California.
-
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
11/10/2022
MannKind Corporation announced that it will present data from two posters on November 10 during the 22nd Annual Diabetes Technology Meeting’s virtual poster session.
-
MannKind Corporation Reports 2022 Third Quarter Financial Results
11/8/2022
MannKind Corporation reported financial results for the third quarter and nine months ended September 30, 2022.
-
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
11/1/2022
MannKind Corporation will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM on Tuesday, November 8, 2022.
-
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
9/21/2022
MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.
-
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
9/6/2022
MannKind Corporation announced that it has successfully completed a Phase 1 study of clofazimine inhalation suspension and is planning discussions with the U.S. Food and Drug Administration regarding results and the ongoing clinical program.
-
MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
9/1/2022
MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 12:00 PM ET at the Lotte New York Palace Hotel.
-
MannKind Corporation Reports 2022 Second Quarter Financial Results
8/9/2022
MannKind Corporation reported financial results for the second quarter and first half of 2022.
-
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
8/2/2022
MannKind Corporation will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM on Tuesday, August 9, 2022.
-
MannKind Corporation to Participate in the BTIG Biotechnology Conference
8/1/2022
MannKind Corporation, a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven Binder will participate in the BTIG Biotechnology Conference taking place on Monday, August 8 – Tuesday, August 9, 2022.
-
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
6/3/2022
MannKind Corporation will showcase its mealtime insulin solutions and expanding efforts within the diabetes community at the American Diabetes Association’s 82nd Scientific Sessions, June 3-7 in New Orleans.
-
Tyvaso DPI marks the first approval of a dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
-
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
5/24/2022
MannKind Corporation celebrated that the U.S. Food and Drug Administration has approved United Therapeutics’ Tyvaso DPI™ inhalation powder for the treatment of patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
-
Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device
5/17/2022
Zealand Pharma Announces Asset Purchase Agreement withMannKind Corporation forV-Go®Insulin Delivery Device
-
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
5/17/2022
MannKind Corporation announced that it has entered into an agreement with Zealand Pharma A/S to acquire V-Go® for $10 million, with additional sales-based milestones plus the cost of certain inventory.